Data Insights

Obinutuzumab by F. Hoffmann-La Roche for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)

Data Insights

Obinutuzumab by F. Hoffmann-La Roche for Mantle Cell Lymphoma: Likelihood of Approval

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Mantle Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Mantle Cell Lymphoma

Data Insights

Obinutuzumab by F. Hoffmann-La Roche for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL)....

Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

Obinutuzumab by F. Hoffmann-La Roche for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL)....

Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia (CLL)

Data Insights

Obinutuzumab by F. Hoffmann-La Roche for Kidney Disease (Nephropathy): Likelihood of Approval

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Kidney Disease (Nephropathy). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Kidney Disease (Nephropathy)

Data Insights

Obinutuzumab by F. Hoffmann-La Roche for Cutaneous T-Cell Lymphoma: Likelihood of Approval

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Cutaneous T-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Cutaneous T-Cell Lymphoma

Data Insights

Obinutuzumab by F. Hoffmann-La Roche for Lupus Nephritis: Likelihood of Approval

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Lupus Nephritis. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Lupus Nephritis

Data Insights

Obinutuzumab by F. Hoffmann-La Roche for Metastatic Melanoma: Likelihood of Approval

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Metastatic Melanoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Metastatic Melanoma

Data Insights

Obinutuzumab by F. Hoffmann-La Roche for Graft Versus Host Disease (GVHD): Likelihood of Approval

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Graft Versus Host Disease (GVHD)....

Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Graft Versus Host Disease (GVHD)

Data Insights

Obinutuzumab by F. Hoffmann-La Roche for Systemic Lupus Erythematosus: Likelihood of Approval

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Systemic Lupus Erythematosus. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Systemic Lupus Erythematosus

Data Insights

Obinutuzumab by F. Hoffmann-La Roche for Hairy Cell Leukemia: Likelihood of Approval

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Hairy Cell Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Hairy Cell Leukemia

Data Insights

Obinutuzumab by F. Hoffmann-La Roche for Nephrotic Syndrome: Likelihood of Approval

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Nephrotic Syndrome. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Nephrotic Syndrome

Data Insights

Obinutuzumab by F. Hoffmann-La Roche for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Splenic Marginal Zone B-Cell Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Splenic Marginal Zone B-Cell Lymphoma